AstraZeneca Archives -

Market Access/ News/ News/ News/ News/ Patients/ Sales and Marketing

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

Phil Taylor access, AstraZeneca, coronavirus, COVID-19, Evusheld, procurement, UK 0 Comment

Half a million people in the UK with conditions like blood cancer that prevents them being protected from

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ News/ Oncology/ R&D

AZ and Daiichi’s TROP2 ADC shows promise in first-line lung cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, Gilead Sciences, Trodelvy 0 Comment

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate DS-1062,

AZ and Daiichi’s TROP2 ADC shows promise in first-line lung cancer

https://pharmaphorum.com/news/az-and-daiichis-trop2-adc-shows-promise-in-first-line-lung-cancer/

News/ News/ News/ Oncology/ R&D

Tagrisso paired with Hutchmed drug clears lung cancer test

Phil Taylor AstraZeneca, HutchMed, Non-small cell lung cancer, Oncology, Orpathys, Tagrisso, targeted oncology 0 Comment

EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of

Tagrisso paired with Hutchmed drug clears lung cancer test

https://pharmaphorum.com/news/tagrisso-paired-with-hutchmed-drug-clears-lung-cancer-test/

Market Access/ News/ News/ News/ Oncology

AZ gets FDA nod for Enhertu in first HER2-low cancer

Phil Taylor AstraZeneca, breast cancer, Enhertu, fda, her2, Oncology, regulatory approval 0 Comment

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for HER2-low breast cancer,

AZ gets FDA nod for Enhertu in first HER2-low cancer

https://pharmaphorum.com/news/az-gets-fda-nod-for-enhertu-in-first-her2-low-cancer/

Radiology technician examens mammography test

News/ News/ News/ Oncology/ Sales and Marketing

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

Phil Taylor adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology 0 Comment

The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant treatment for breast cancer,

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-eu-nod-for-lynparza-as-adjuvant-breast-cancer-therapy/

News/ News/ News/ Oncology/ R&D

AZ, Innate’s checkpoint inhibitor monalizumab flunks phase 3 test

Phil Taylor AstraZeneca, head and neck cancer, immuno-oncology, Innate Pharma, monalizumab, NKG2A, Oncology, partnering 0 Comment

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer,

AZ, Innate’s checkpoint inhibitor monalizumab flunks phase 3 test

https://pharmaphorum.com/news/az-innates-checkpoint-inhibitor-monalizumab-flunks-phase-3-test/

News/ News/ Sales and Marketing

AstraZeneca raises 2022 guidance, names Demaré as non-exec chair

Phil Taylor AstraZeneca, Enhertu, Evusheld, Farxiga, Financial, Oncology, Rare diseases 0 Comment

AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its

AstraZeneca raises 2022 guidance, names Demaré as non-exec chair

https://pharmaphorum.com/news/astrazeneca-raises-2022-guidance-names-demare-as-non-exec-chair/

News/ News/ Oncology

FDA verdict on Enhertu in HER2-low breast cancer due before year-end

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, fda, her2, Oncology 0 Comment

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license

FDA verdict on Enhertu in HER2-low breast cancer due before year-end

https://pharmaphorum.com/news/fda-verdict-on-enhertu-in-her2-low-breast-cancer-due-before-year-end/

Market Access/ News/ News/ News/ Oncology

Roche’s fast-growing eye drug Vabysmo set for EU approval

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, AstraZeneca, Bristol-Myers Squibb, CHMP, Eli Lilly, Eylea, Mounjaro, Opdualag, ophthalmology, Roche, Tezspire, Vabysmo 0 Comment

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on

Roche’s fast-growing eye drug Vabysmo set for EU approval

https://pharmaphorum.com/news/roches-fast-growing-eye-drug-vabysmo-set-for-eu-approval/

Trending

AstraZeneca

Login